


Supplementary Table 1. Association of proton pump inhibitors exposure with the development of renal failure adjusted for patient characteristics and other exposures.

Baseline characteristics	OR (95%CI)	P value
PPIs	1.27 (1.09-1.48)	0.002
Gender	0.90 (0.77-1.05)	0.189
40-49 years	1.38 (0.95-2.02)	0.089
50-59 years	1.34 (0.95-1.89)	0.089
60-69 years	1.49 (1.07-2.07)	0.017
70-79 years	1.51 (1.08-2.11)	0.015
>= 80 years.	1.57 (1.11-2.21)	0.010
Trauma	0.70 (0.55-0.88)	0.003
Sepsis	1.47 (1.24-1.76)	0.000
Myocardial infarction	1.23 (1.00-1.53)	0.047
Congestive heart failure	1.33 (1.11-1.59)	0.002
Hypertension	1.14 (0.94-1.39)	0.175
Diabetes	0.98 (0.82-1.18)	0.901
Cerebrovascular disease	0.74 (0.60-0.93)	0.009
Chronic pulmonary disease	0.98 (0.82-1.16)	0.826
Connective tissue disease	1.10 (0.73-1.66)	0.642
Ulcer disease	1.22 (0.80-1.87)	0.347
Liver disease	1.73 (1.45-2.07)	0.000
Metastatic tumor	1.59 (1.17-2.16)	0.003
Vancomycin	2.40 (1.93-2.99)	0.000
Meropenem	1.46 (1.17-1.82)	0.001
Aminoglycosides	1.55 (1.17-2.05)	0.002
Piperacillin-Tazobactam	1.49 (1.27-1760)	0.000
Contrast medium	1.44 (1.14-1.81)	0.002

Supplementary Figure 1. Odds ratio of exposure to proton pump inhibitors.



Supplementary Figure 2. Odds ratio of factors associated with AKI.

